Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a computer help pick the right ADHD medicine for your child?

NCT ID NCT07812948

Knowledge-focused Sponsor: University of Southampton Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 10, 2026 · Last updated Sep 11, 2026 · Updated 1 time

Summary

Children with ADHD often try several medicines before finding one that works well. Researchers are testing PETRA, an online decision-support tool that uses personal data and research evidence to suggest three medication options for each child. The study enrolls children aged 6 to 17 who are waiting for ADHD medication, along with their parents or carers. It checks whether families and doctors find the tool acceptable and whether a larger trial comparing PETRA with standard care is practical.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
PETRA, an online decision-support tool that uses personalised data to suggest ADHD medications
What this could lead to
If PETRA proves practical and acceptable, it could support a larger trial testing whether personalised medication choices help children find an effective ADHD medicine sooner.
What could go wrong
This is a small feasibility study, so it cannot show whether PETRA improves outcomes. The tool may not fit busy clinics, and families may find it hard to use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 102 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Nov 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 to 17 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Children/adolescents: * Aged 6-17 years * With a clinical diagnosis of ADHD by a clinical team (using either DSM-5-TR or ICD-11 criteria) * On the waiting list for the pharmacological treatment of ADHD Inclusion criteria for parent/carer: * Parental responsibility * Knowledge of child's medical history sufficient to complete assessments. * Access to internet and email * Able to give valid informed consent * Sufficient understanding of English to allow access/understanding of the PETRA decision support system and study documentation Exclusion Criteria: * Based on the clinical judgement of the prescribing clinician, any current condition that would be a contraindication for ADHD medication, including abnormal cardiovascular examination (i.e., BP\>95th percentile (for stimulants) and low blood pressure for guanfacine/clonidine as well as tachycardia ) or any conditions that should be treated before starting pharmacological treatment for ADHD such as alcohol/substance dependence, active psychosis, and active mania * Immediate risk to self or others

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADHD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

attention deficit hyperactivity disorder, inattentive type attention deficit-hyperactivity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADHD

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.